Immune Plasma for the Treatment of COVID-19: Lessons Learned so far
Hämostaseologie · 01.02.2023 · 43 (01) · 067-074
DOI: 10.1055/a-1987-3682 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hämostaseologie, erschienen am 01.02.2023. Verfasst von Hubert Schrezenmeier und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and, Univers…. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben.
Abstract (Originalsprache)
COVID-19 convalescent plasma (CCP) has been explored as one of the treatment options for COVID-19. Results of many cohort studies and clinical trials have been recently published. At first glance, the results of the CCP studies appear to be inconsistent. However, it became clear that CCP is not beneficial if CCP with low anti-SARS-CoV-2 antibody concentrations is used, if it is administered late in advanced disease stages, and to patients who already mounted an antibody response against SARS-CoV-2 at the time of CCP transfusion. On the other hand, CCP may prevent progression to severe COVID-19 when very high-titer CCP is given early in vulnerable patients. Immune escape of new variants is a challenge for passive immunotherapy. While new variants of concern developed resistance to most clinically used monoclonal antibodies very rapidly, immune plasma from individuals immunized by both a natural SARS-CoV-2 infection and SARS-CoV-2 vaccination retained neutralizing activity against variants. This review briefly summarizes the evidence on CCP treatment to date and identifies further research needs. Ongoing research on passive immunotherapy is not only relevant for improving care for vulnerable patients in the ongoing SARS-CoV-2 pandemic, but even more as a model for passive immunotherapy in case of future pandemics with a newly evolving pathogen. Compared to other drugs, which must be newly developed in a pandemic (e.g., monoclonal antibodies, antiviral drugs), convalescent plasma is rapidly available, inexpensive to produce, and can be adaptive to viral evolution by selection of contemporary convalescent donors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and, University Hospital Ulm, Ulm, Germany.
- Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.
- Institute of Transfusion Medicine and Immunohematology, German Red Cross Blood Transfusion Service Baden-Württemberg - Hessen, Frankfurt, Germany.
Zitieren
APA
Schrezenmeier, H., Hoffmann, S., Hofmann, H., Appl, T., Jahrsdörfer, B., Seifried, E., & Körper, S. (2023). Immune Plasma for the Treatment of COVID-19: Lessons Learned so far. Hämostaseologie, 43(01), 067-074. https://doi.org/10.1055/a-1987-3682
Vancouver
Schrezenmeier H, Hoffmann S, Hofmann H, Appl T, Jahrsdörfer B, Seifried E, et al. Immune Plasma for the Treatment of COVID-19: Lessons Learned so far. Hämostaseologie. 2023;43(01):067-074. doi:10.1055/a-1987-3682
BibTeX
@article{Schrezenmeier2023,
author = {Schrezenmeier, Hubert and Hoffmann, Simone and Hofmann, Henrike and Appl, Thomas and Jahrsdörfer, Bernd and Seifried, Erhard and Körper, Sixten},
title = {Immune Plasma for the Treatment of COVID-19: Lessons Learned so far},
journal = {Hämostaseologie},
year = {2023},
volume = {43},
number = {01},
pages = {067--074},
doi = {10.1055/a-1987-3682}
}
EUVIMED